

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021164-000100US

Assistant Commissioner for Patents
Washington, D.C. 20231

On November 16, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wen-Ghieh Tsang
Tianli Zheng
Chang Jiang Huang

Application No.: 09/895,585

Filed: June 29, 2001

For: CULTURING PANCREATIC
STEM CELLS HAVING A SPECIFIED,
INTERMEDIATE STAGE OF
DEVELOPMENT

Examiner: Not known

Art Unit: 1636

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kenneth A. Weber
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KAW:jhd



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449APTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Compl to H Kn wn

Application Number

09/895,585

Filing Date

June 28, 2001

First Named Inventor

Tsang, Wen-Ghih

Group Art Unit

1636

Examiner Name

Not known

Attorney Docket Number

021164-000100US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	US 2001/0000324	A1	Todorov et al.	04-19-2001	
	AB	5,888,616		Coon et al.	03-30-1999	
	AC	5,828,942		Brothers	07-27-1999	
	AD	5,739,033		Soon-Shiong	04-14-1998	
	AE	6,001,647		Peck et al.	12-14-1999	
	AF					
	AG					
	AH					
	AI					
	AJ					

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	BA	PCT	WO 00/47721	A2	Ontogeny, Inc.	08-17-2000		
	BB	PCT	WO 99/61588	A1	Desmos, Inc.	12-02-1999		
	BC	PCT	WO 00/78929	A1	Joslin Diabetes Center, Inc.	12-28-2000		
	BD							
	BE							
	BF							

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1281585 v1

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Compl to If Known	
		Applicati n Number	09/895,585
		Filing Date	June 29, 2001
		First Named Inventor	Tsang, Wen-Ghih
		Group Art Unit	1636
		Examiner Name	Not known
Sheet 2 of 2	Attorney Docket Number	021164-000100US	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	001	Bonner-Weir, S., et al., "In vitro cultivation of human islets from expanded ductal tissue," <i>PNAS</i> , 97(14):7999-8004 (July 5, 2000).	
	002	Gmyr, V., et al., "Adult Human Cytokeratin 19-Positive Cells Reexpress Insulin Promoter Factor 1 In Vitro Further Evidence for Pluripotent Pancreatic Stem Cells in Humans," <i>Diabetes</i> , 49:1671-1680 (October 2000).	
	003	Peck, A. B., et al., "Pancreatic stem cells: building blocks for a better surrogate islet to treat type 1 diabetes," <i>Ann Med</i> , 33:186-192 (2001).	
	004	Ryan, E. A., et al., "Clinical Outcomes and Insulin Secretion after Islet Transplantation with the Edmonton Protocol," <i>Diabetes</i> , 50:710-719 (April 2001).	
	005	Shapiro, A. M. J., et al., "Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen," <i>New England J. of Med.</i> , 343:230 (July 27, 2000).	
	006	Soon-Shiong, P., et al., "Long-term reversal of diabetes by the injection of immunoprotected islets," <i>Proc. Natl. Acad. Sci. USA</i> , 90:5843-5847 (June 1993).	
	007	Stephan, J.-P., et al., "Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation," <i>Endocrinology</i> , 140(12):5841-5854 (1999).	
	008	Zhou, Y.-T., et al., "Leptin Normalizes the Impaired Response of Proinsulin mRNA to Long Chain Fatty Acids in Heterozygous Zucker Diabetic Fatty Rats," <i>J. Biol. Chem.</i> , 272(41):25648-25651 (1997).	
	009	Zukewski, H., et al., "Multipotential Nestin-Positive Stem Cells Isolated from Adult pancreatic Islets Differentiate Ex Vivo into Pancreatic Endocrine, Exocrine, and Hepatic Phenotypes," <i>Diabetes</i> , 50:521-533 (March 2001).	
	010		
	011		

SF 1281585 v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1281585 v1